EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identification of a Selective Cell‐Active Inhibitor of Protein Arginine Methyltransferase 5 ( PRMT5 ) for the Treatment of Prostate Cancer by Structure‐Based Virtual Screening

TongXiang Diao, Chen Feng, Shuai Liu, Jia-Li Song, Kong-Kai Zhu, Cheng-Shi Jiang, Qiang Fu

Chemical Biology & Drug Design · 2025-06 · 105 (6)

DOI: 10.1111/cbdd.70136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 04.06.2025. Verfasst von TongXiang Diao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Prostatic Neoplasms, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Key Technology Research and Development Program of Shandong Province, Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein arginine methyltransferase 5 (PRMT5) is an epigenetic‐related enzyme that has been shown to be a promising target for the treatment of human cancers. In prostate cancer, gene knockout has been shown to inhibit cancer cells by regulating the androgen receptor (AR), but this method has no effect on advanced prostate cancer without AR expression, and existing anticancer drugs are effective only in the current stage and promote the progression of cancer to advanced prostate cancer. We hope to design and synthesize a new compound that can inhibit prostate cancer at different stages. A series of candidate PRMT5 inhibitor molecules were designed on the basis of virtual molecular docking screening, and the binding mode was predicted via molecular docking simulation. Prostate cancer cell proliferation was detected by CCK‐8, EdU, and flow assays, which verified the changes in the cancer cell cycle. Migration and invasion assays verified the effects of the compounds on the metastatic function of prostate cancer cells. Finally, Western blotting was used to detect the mechanism of action of the compounds in the treatment of prostate cancer. In prostate cancer, gene knockout has been shown to inhibit cancer cells by regulating the AR, but it has no effect on advanced prostate cancer without AR expression, and existing anticancer drugs are effective only in the current stage and promote the progression of cancer to advanced prostate cancer. SJL2‐1 may be a promising compound for novel therapies for early androgen‐sensitive prostate cancer and advanced castration‐resistant prostate cancer (CRPC).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-MethyltransferasesProstatic NeoplasmsAntineoplastic AgentsEnzyme InhibitorsHumansMaleMolecular Docking SimulationCell ProliferationCell Line, TumorCell MovementBinding SitesDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

PRMT5 inhibitorarginine methylationmolecular dockingprostate cancervirtual screening

Substanzen

Protein-Arginine N-MethyltransferasesPRMT5 protein, humanAntineoplastic AgentsEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Engineering Laboratory of Urinary Organ and Functional Reconstruction of Shandong Province, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
  • School of Biological Science and Technology, University of Jinan, Jinan, Shandong, China.

Förderung

  • Key Technology Research and Development Program of Shandong Province
  • Natural Science Foundation of Shandong Province
  • National Natural Science Foundation of China

Zitieren

APA

Diao, T., Feng, C., Liu, S., Song, J. L., Zhu, K. K., Jiang, C. S., & Fu, Q. (2025). Identification of a Selective Cell‐Active Inhibitor of Protein Arginine Methyltransferase 5 ( PRMT5 ) for the Treatment of Prostate Cancer by Structure‐Based Virtual Screening. Chemical Biology & Drug Design, 105(6). https://doi.org/10.1111/cbdd.70136

Vancouver

Diao T, Feng C, Liu S, Song JL, Zhu KK, Jiang CS, et al. Identification of a Selective Cell‐Active Inhibitor of Protein Arginine Methyltransferase 5 ( PRMT5 ) for the Treatment of Prostate Cancer by Structure‐Based Virtual Screening. Chemical Biology & Drug Design. 2025;105(6). doi:10.1111/cbdd.70136

BibTeX
@article{Diao2025,
  author = {Diao, TongXiang and Feng, Chen and Liu, Shuai and Song, Jia-Li and Zhu, Kong-Kai and Jiang, Cheng-Shi and Fu, Qiang},
  title = {Identification of a Selective Cell‐Active Inhibitor of Protein Arginine Methyltransferase 5 ( PRMT5 ) for the Treatment of Prostate Cancer by Structure‐Based Virtual Screening},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  volume = {105},
  number = {6},
  doi = {10.1111/cbdd.70136}
}
Kostenlos starten →